Bli medlem
Bli medlem

Du är här

2019-04-30

AstraZeneca: AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery

Collaboration with BenevolentAI will use machine learning and
artificial intelligence to discover potential new drugs for chronic
kidney disease and idiopathic pulmonary fibrosis

AstraZeneca and BenevolentAI today began a long-term collaboration to
use artificial intelligence (AI) and machine learning for the
discovery and development of new treatments for chronic kidney
disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Scientists from the two organisations will work side-by-side to
combine AstraZeneca's genomics, chemistry and clinical data with
BenevolentAI's target identification platform and biomedical
knowledge graph - a network of contextualised scientific data (genes,
proteins, diseases and compounds) and the relationship between them.

Machine learning systematically analyses data to find connections
between facts, and AI-based reasoning is used to extrapolate
previously unknown connections. Together, the companies will
interpret the results to understand the underlying mechanisms of
these complex diseases and more quickly identify new potential drug
targets.

Mene Pangalos, Executive Vice President and President
BioPharmaceuticals R&D, said: "The vast amount of data available to
research scientists is growing exponentially each year. By combining
AstraZeneca's disease area expertise and large, diverse datasets with
BenevolentAI's leading AI and machine learning capabilities, we can
unlock the potential of this wealth of data to improve our
understanding of complex disease biology and identify new targets
that could treat debilitating diseases."

Joanna Shields, Chief Executive Officer, BenevolentAI, said: "Millions
of people today suffer from diseases that have no effective
treatment. The future of drug discovery and development lies in
bridging the gap between AI, data, and biology. We are thrilled to be
joining forces with AstraZeneca to develop new insights and identify
promising new treatments for chronic kidney disease and idiopathic
pulmonary fibrosis."

CKD and IPF are complex diseases in which the underlying disease
biology is poorly understood. This disease complexity requires the
interrogation of vast, rich datasets.

BenevolentAI is a global AI leader focused on drug discovery. The
company has developed the Benevolent Platform, an AI discovery
platform which can be used by scientists to try to discover novel
pathways and mechanisms important in the pathophysiology of disease.

- ENDS -

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal & Metabolism
and Respiratory. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide. For
more information, please visit astrazeneca.com and follow us on
Twitter @AstraZeneca.

Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharma +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Sweden +46 8 552 53 106
Malmberg
Hägerstrand
Michele US +1 302 885 2677
Meixell

Investor
Relations
Thomas Kudsk +44 203 749 5712
Larsen
Henry Wheeler Oncology +44 203 749 5797
Christer BioPharma (cardiovascular; metabolism) +44 203 749 5711
Gruvris
Nick Stone BioPharma (respiratory, renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Corporate access, retail investors +44 203 749 5824
Kretzmann
US toll-free +1 866 381 72 77

-----------------------------------------------------------
https://news.cision.com/se/astrazeneca/r/astrazeneca-starts-artificial-i...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.